Eli Lilly to buy three small vaccine developers The companies are working on shots against pathogens that can cause long-term health issues

https://www.statnews.com/2026/05/26/eli-lilly-acquisitions-vaccine-developers/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-8ALuHnUhg-wOSdJnkpBSgzTtMBEBG8SW_G2msUBKnpeTSgTJ3rhJJUvJxIppiL2shtOjfJw4BPpXxQSB3n6vxw_53s1Q&_hsmi=420539245&utm_content=420539245&utm_source=hs_email By Andrew JosephMay 26, 2026 Europe Correspondent Lilly is also spending more of its GLP-1 cash Indeed, this morning brings another round of deal-making for Lilly. The pharma giant announced plans to acquire three early and mid-stage vaccine developers for a combined $4 billion, my colleague Andrew Joseph reports. The companies being bought are Curevo, LimmaTech Biologics, and Vaccine Company. The new acquisitions will give Lilly a much larger footprint in infectious diseases, an area that hasn’t recently been a priority for the company. Lilly framed the move as one that fit with a broader focus on preventing serious health problems.